Aastrom Biosciences to Present New Findings on Atheroprotective Effects of Ixmyelocel-T at Keystone Symposia on Atherosclerosis
27 March 2012 - 12:15AM
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of
patient-specific, expanded multicellular therapies for the
treatment of severe, chronic cardiovascular diseases, today
announced that results from a preclinical study demonstrating the
potential atheroprotective properties of ixmyelocel-T will be
presented in a poster session at the Keystone Symposia on the
Molecular Basis of Vascular Inflammation and Atherosclerosis in Big
Sky, Montana starting Sunday, March 25, 2012. The poster is
entitled "Ixmyelocel-T therapy alternatively activated macrophages
potentially exert atheroprotective effects."
In clinical trials, ixmyelocel-T has shown promise in the
treatment of severe, chronic ischemic and inflammatory diseases
associated with atherosclerosis. Ixmyelocel-T therapy is an
investigational, patient-specific, multicellular therapy expanded
from a patient's own bone marrow and comprised primarily of CD90+
mesenchymal stromal cells (MSCs) and CD14+autofluorescent+
alternatively activated macrophages. These macrophages have been
identified by the secretion of anti-inflammatory cytokines,
expression of scavenger receptors and the upregulation of reverse
cholesterol transporter proteins. This study represents the first
report of expansion of this cell type in vitro.
Advanced atherosclerotic disease and its associated arterial
lesions (atheroma) are characterized by lipid accumulation, chronic
inflammation and defective removal of apoptotic cells. In this in
vitro study, alternatively activated macrophages in ixmyelocel-T
demonstrated key functions in the resolution of atherosclerotic
lesions: active removal of apoptotic cells and reverse cholesterol
transport.
Aastrom scientists are currently evaluating the characteristics
and therapeutic potential of alternatively activated macrophages,
which are a cell population unique to Aastrom's patented cellular
therapy.
About Aastrom Biosciences
Aastrom Biosciences is the leader in developing
patient-specific, expanded multicellular therapies for use in the
treatment of patients with severe, chronic cardiovascular
diseases. The company's proprietary cell-processing technology
enables the manufacture of ixmyelocel-T, a patient-specific
multicellular therapy expanded from a patient's own bone marrow and
delivered directly to damaged tissues. Aastrom has advanced
ixmyelocel-T into late-stage clinical development, including a
Phase 3 clinical program to study patients with critical limb
ischemia and a planned Phase 2b clinical trial in patients with
ischemic dilated cardiomyopathy. For more information, please visit
Aastrom's website at www.aastrom.com. For more information on
the pivotal REVIVE Phase 3 clinical trial, please visit the trial
website at www.revivecli.com.
The Aastrom Biosciences, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3663
This document contains forward-looking statements, including,
without limitation, statements concerning clinical trial plans and
progress, objectives and expectations, clinical activity timing,
intended product development, the performance and contribution of
certain individuals and expected timing of collecting and analyzing
treatment data, all of which involve certain risks and
uncertainties. These statements are often, but are not always, made
through the use of words or phrases such as "anticipates,"
"intends," "estimates," "plans," "expects," "we believe," "we
intend," and similar words or phrases, or future or conditional
verbs such as "will," "would," "should," "potential," "could,"
"may," or similar expressions. Actual results may differ
significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are the inherent uncertainties associated with clinical
trial and product development activities, regulatory approval
requirements, competitive developments, and the availability of
resources and the allocation of resources among different potential
uses. These and other significant factors are discussed in greater
detail in Aastrom's Annual or Transition Report on Form 10-K or
10-K/T, Quarterly Reports on Form 10-Q and other filings with the
Securities and Exchange Commission. These forward-looking
statements reflect management's current views and Aastrom does not
undertake to update any of these forward-looking statements to
reflect a change in its views or events or circumstances that occur
after the date of this release except as required by law.
CONTACT: Media contact
Andrea Coan
Berry & Company
acoan@berrypr.com
(212) 253-8881
Investor contact
Danielle Spangler
The Trout Group
dspangler@troutgroup.com
(646) 378-2924
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Jul 2024 to Aug 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Aug 2023 to Aug 2024